Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bayer_AG
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focus |
immunology
oncology small molecule drug discovery |
| gptkbp:foundedYear |
2013
|
| gptkbp:founder |
gptkb:Phil_Baran
gptkb:Jin-Quan_Yu gptkb:Benjamin_F._Cravatt |
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vividion Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
Jeffrey Hatfield
|
| gptkbp:numberOfEmployees |
100-200
|
| gptkbp:parentCompany |
gptkb:Bayer_AG
|
| gptkbp:website |
https://www.vividion.com/
|
| gptkbp:bfsParent |
gptkb:The_Column_Group
gptkb:Versant_Ventures |
| gptkbp:bfsLayer |
7
|